Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | February 06, 2019 | February 08, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | October 14, 2020 | October 16, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 03, 2021 | March 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,887,225 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 7,745 · Balance 2,885,507 F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 2 · 2019-02-06 · Grant · Acquired 15,505 · Balance 2,901,012 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 13,787 · Balance 2,887,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Kronos Bio, Inc.
Report date October 14, 2020 · Filed October 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,952,364 |
Last balance in matching sequence
After 2020-10-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-10-14 · Conversion · Acquired 914,333 · Balance 914,333 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-10-14 · Conversion · Acquired 756,971 · Balance 1,671,304 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-10-14 · Conversion · Acquired 205,260 · Balance 1,876,564 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-10-14 · Purchase · Acquired 75,800 · Balance 1,952,364 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-14 · Conversion · Disposed 866,667 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-14 · Conversion · Disposed 717,509 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2022-02-20 | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-14 · Conversion · Disposed Not disclosed · Balance 0 F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Sarepta Therapeutics, Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,913 |
Reported balance
After 2021-03-03 transaction · row 1
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 2,726 · Balance 7,913 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.11 · Expires 2031-03-03 | Direct | 5,518 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 5,518 · Balance 5,518 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · derivative · entry 11 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,720 Underlying: Common Stock · 120,000 shares Expires 2006-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested in equal annual installments over five years beginning 4/24/97, the first anniversary date of the grant. Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $39.05 | $390,500.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 10 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 30,000 | $39.00 | $1,170,000.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 9 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.85 | $388,500.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 8 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.84 | $388,400.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 20,000 | $38.80 | $776,000.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.77 | $387,700.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 762,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.75 | $387,500.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.70 | $387,000.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon stock | 10,000 | $38.62 | $386,200.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,858 Read SEC document |
| May 05, 2005 Filed May 6, 2005 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 120,000 | $4.09 | $491,256.00 |
DisclosureSEC source: 0001179110-05-009167 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All share and dollar amounts reflect a two-for-one stock split effective September 3, 2004, benefitting all stockholders of record as of August 12, 2004. Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified stock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · derivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,720 Underlying: Common Stock · 35,000 shares Expires 2006-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested in equal annual installments over five years beginning on April 24, 1997, the first anniversary date of the grant. The options were fully vested as of April 24, 2001. Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,625 | $35.40 | $92,925.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,858 Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,375 | $34.95 | $257,756.25 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,483 Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $34.75 | $173,750.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,858 Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $34.71 | $347,100.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,858 Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $34.65 | $346,500.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,858 Read SEC document |
| February 25, 2005 Filed Mar 1, 2005 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 35,000 | $4.09 | $143,283.00 |
DisclosureSEC source: 0001179110-05-004337 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All share and dollar amounts reflect a two-for-one stock split effected on 9/3/04 benefitting all stockholders as of 8/12/04. Read SEC document |
| February 15, 2005 Filed Feb 15, 2005 21:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-05-003498 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,858 F2 · kind: Shares given as a gift to a not-for-profit organization. Read SEC document |
| February 15, 2005 Filed Feb 15, 2005 21:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-05-003498 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,936 F2 · kind: Shares given as a gift to a not-for-profit organization. F1 · balance_after: All shares and dollar amounts reflect a two-for-one stock split effective September 3, 2004 benefitting all stockholders of record as of August 12, 2004. Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified stock option (right to buy) · Derivative | 85,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · derivative · entry 10 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,720 Underlying: Common Stock · 85,000 shares Expires 2006-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested in equal annual installments over five years beginning on April 24, 1997, the first anniversary date of the grant. The options were fully vested as of April 24, 2001. Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $32.24 | $322,400.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 9 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $32.27 | $322,700.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 8 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $32.20 | $322,000.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $32.12 | $321,200.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,500 | $32.10 | $240,750.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,500 | $32.01 | $400,125.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,514 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $31.50 | $315,000.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $31.75 | $476,250.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,014 Read SEC document |
| February 09, 2005 Filed Feb 10, 2005 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 85,000 | $4.09 | $347,973.00 |
DisclosureSEC source: 0001179110-05-002970 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All share and dollar amounts reflect a two-for-one stock split effected on 9/3/04 benefitting all stockholders as of 8/12/04. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 421,877 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001853 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,877 Underlying: Common Stock · 421,877 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| January 26, 2005 Filed Jan 28, 2005 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 3,123 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-001853 · edgar.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,123 Underlying: Common Stock · 3,123 shares Expires 2015-01-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 26, 2006, the first anniversary date of the grant. The balance will vest every three months thereafter until fully vested on January 26, 2015. Read SEC document |
| December 30, 2004 Filed Dec 31, 2004 01:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001179110-04-024300 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,640 Underlying: Common Stock · 20,000 shares Expires 2007-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested 20% annually beginning on 7/16/98, the first anniversary date of the grant. The option was fully vested as of 7/16/02. Read SEC document |
| December 30, 2004 Filed Dec 31, 2004 01:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $3.27 | $65,314.00 |
DisclosureSEC source: 0001179110-04-024300 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All share and dollar amounts reflect a two-for-one stock split effected on 9/3/04 benefitting all stockholders as of 8/12/04. Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · derivative · entry 25 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,720 Underlying: Common Stock · 120,000 shares Expires 2006-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested 20% annually beginning on April 24, 1997, the first anniversary date of the grant. Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $37.09 | $59,344.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 24 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,014 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $37.00 | $37,000.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 23 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,614 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 962 | $37.03 | $35,622.86 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 22 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,614 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,143 | $37.05 | $227,598.15 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 21 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,576 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,600 | $37.06 | $96,356.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 20 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,719 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $37.07 | $74,140.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 19 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,319 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $37.08 | $14,832.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 18 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,319 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $37.10 | $59,360.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 17 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,719 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,657 | $37.11 | $284,151.27 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 16 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,319 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 29,100 | $37.50 | $1,091,250.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 15 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,976 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $37.51 | $3,751.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 14 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,076 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,638 | $37.52 | $61,457.76 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 13 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,176 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $37.53 | $7,506.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 12 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,814 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $37.58 | $375,800.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 11 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,014 Read SEC document |
| November 05, 2004 Filed Nov 8, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $37.60 | $188,000.00 |
DisclosureSEC source: 0001179110-04-020941 · edgar.xml · nonDerivative · entry 10 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,014 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.